Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoeconomic comparison and patient compliance: short-acting G-CSF vs PEG-G-CSF for primary prevention of chemotherapy-induced neutropenia in breast cancer
ChiCTR2000037800Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of filgrastim and pegfilgrastim in breast cancer and neutropenia (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: FACT-B dimension scores and Pharmacoeconomic analysis questionnaire scores. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
filgrastimpegfilgrastim
03
Conditions
breast cancerneutropenia
Beyond the preview
Go deeper on ChiCTR2000037800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037800.